Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients

Table 2 Changes in the metabolic and cardiovascular profile during PI-therapy

PI group		ATV/r	FPV/r	SQV/r	p-value^a
Characteristic
Number of patients		84	23	17
Serum cholesterol
at baseline [mg/dl]	Median	204	179	173
	(IQR)	(159; 251)	(148; 217)	(143; 221)	0.19
at month 6 [mg/dl]	Median	186	204	209
	(IQR)	(157; 228)	(177; 284)	(164; 278)	0.055
relative change at month 6	% (Median)	-6	+21	+8	0.0002
Serum triglycerides
at baseline [mg/dl]	Median	187	136	205
	(IQR)	(113; 334)	(87; 289)	(143; 366)	0.20
at month 6 [mg/dl]	Median	186	169	218
	(IQR)	(119; 280)	(122; 239)	(120; 342)	0.90
Serum glucose
at baseline [mg/dl]	Median	90	87	89
	(IQR)	(82; 101)	(83; 97)	(78; 99)	0.70
at month 6 [mg/dl]	Median	91	90	97
	(IQR)	(83; 101)	(83; 103)	(89; 118)	0.17
High cardiovascular risk ^b
at baseline	n (%)	23 (27)	2 (9)	2 (12)	0.088
at month 6	n (%)	20 (24)	3 (13)	3 (18)	0.50

^a: Kruskal-Wallis-H-test for metric variables; p-value for inter-group comparisons
^b: risk of developing a fatal cardiovascular event over the next ten years >5%, according to the HeartScore [2, 3, 53]

ISSN: 2047-783X